MBL77 OPTIONS

For individuals with symptomatic disease necessitating therapy, ibrutinib is commonly recommended based on four stage III randomized clinical trials evaluating ibrutinib with chlorambucil monotherapy106 as well as other commonly utilised CIT mixtures, specifically FCR, bendamustine moreover rituximab and chlorambucil furthermore obinutuzumab (ClbO)